Ascensia Diabetes Care announced today that it launched the Senseonics (NYSE:SENS) Eversense E3 system in the U.S.
The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S.
Get the full story at our sister site, Drug Delivery Business News.